Could a cheap Fat-Lowering drug shield kidneys in type 1 diabetes?

NCT ID NCT04929379

Ongoing Prevention Sponsor: Alessandro Doria Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether fenofibrate, a generic drug used to lower blood fats, can prevent kidney function loss in people with type 1 diabetes who are at high risk of kidney failure. Forty participants will receive either fenofibrate or a placebo for 18 months, and their kidney function will be measured. The goal is to gather data for a larger trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC NEPHROPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC NEPHROPATHIES

Contacts and locations

Show contact details

Locations

Brehm Center for Diabetes Research / University of Michigan

Ann Arbor, Michigan, 48105, United States
Joslin Diabetes Center

Boston, Massachusetts, 02215, United States
Lahey Hospital and Medical center

Burlington, Massachusetts, 01805, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States